AMILO-LATAM

Grupo Latinoamericano de Investigación en
Amiloidosis Cardiaca// Latin American Research Group on Cardiac Amyloidosis. Contact: [email protected]

[AMILO-LATAM @AmiloLATAM]

Participando en #CongresoSIAC #SIAC2024 #SIAC24 mostrando parte de nuestro trabajo de Investigación del Gpo #AmiloLATAM @SIAC_cardio

[The International Society Of Amyloidosis @ISA_Amyloidosis]

ISA names Dr. Morie Gertz as the 2026 Giampaolo Merlini Award recipient, recognizing his outstanding contributions to clinical and translational research.

He will deliver the Giampaolo Merlini Lecture at ISA 2026 in Montevideo.

Register now and join us: https://t.co/78D32k0pqX

[Ahmad Masri @MasriAhmadMD]

Data from ATTRibute-CM on the NTproBNP response in the subgroup of variant ATTR patients. Acoramidis mitigated the rise of NTproBNP as compared to placebo
#HFSA2025
#CardioTwitter
#MedIQHFSA2025

[Ala W. Abdallah @AlaAbdallah_md]

Thrilled to share that our review “What Cardiologists Should Know About Amyloidosis” is now published in the Journal of Clinical Medicine!

Highlighting early recognition, diagnostics, and therapies for cardiac amyloidosis.

🔗 https://t.co/US7ubns1wJ

#CardioTwitter #Amyloidosis

[Osejie Oriaifo MD MSc 🫀 @megaoses]

1/5 Just presented a case on cardiac amyloidosis; common yet often underdiagnosed. We walked through diagnosis, management, and especially Afib care. 🫀 #CardioTwitter

[JACC Journals @JACCJournals]

New in #JACC: A cross-trial analysis of 3 cardiac amyloidosis #ATTRCM trials reveals time-dependent effects of modern disease-modifying therapies on mortality.

Get the details: https://t.co/xo5M8XoMXW

#ATTRMeeting2025 #ATTR2025 #Amyloidosis @mvaduganathan @scottdsolomon

[NEJM @NEJM]

Presented at #ATTR:

Gillmore and colleagues report 24-month results from a phase 1 study of nexiguran ziclumeran, a CRISPR gene-editing approach to treating hereditary transthyretin amyloidosis with polyneuropathy. Full study results: https://t.co/vGHsrnnKjd

[Muzaffar Qazilbash @Transplant_Doc]

Nexiguran Ziclumeran (nex-z) Gene Editing in Hereditary ATTR with Polyneuropathy. A single dose of nex-z in patients with ATTRv-PN was associated with rapid, deep, and durable reductions in serum TTR levels #amyloidosis #mmsm @NEJM https://t.co/8n08FFDfcG

[Amyloidosis Research Consortium @Amyloidosis_ARC]

ARC’s Annual Community Survey captures real-world experiences of #amyloidosis and helps guide care, support, & research.

Patients with amyloidosis and their caregivers, we invite you to take part in this year's survey.

👉 Take the survey here: https://t.co/2yKTBxvvQ2

[Ronald Witteles @Ron_Witteles]

More incredible #CRISPR data with #Nexz published today in @NEJM -- this time 2 year data from the Phase 1 #ATTR polyneuropathy study. #TTR levels down 90% by day 28... and 92% at month 24! Improved neuropathy functionally and by #Nfl levels. Exciting prospects for #MAGNITUDE. https://t.co/2tMKXtXx7B

[EHJ Editor-in-Chief @ehj_ed]

Hidden culprit in atrial fibrillation? Biopsy reveals atrial amyloidosis—more common with age and structural heart changes. Read more in #EHJ.
https://t.co/jWe6DKBMmf
#cardiotwitter #AtrialFibrillation #CardiacAmyloidosis #AgingHeart @ESC_Journals @escardio

[Daniel Moro Quesada @danielmoro10]

Amyloidosis therapy @basurto_mayte @ISCPcardio

[Amyloidosis Speakers Bureau @Amyloidosis_ASB]

Great educational opportunity!

The Heart Failure Society of America is hosting a webinar titled "Understanding and Managing ATTR Amyloidosis" on October 22.

If you or someone you know is interested in learning more about this important topic, please check out the informational link provided below.

https://t.co/2Te2KrBho5

[PeerView @PeerView]

Watch Michelle Kittleson, MD, PhD (@MKittlesonMD) & Senthil Selvaraj, MD, MS, MA (@senthil_selv) discuss updates on Implementing Targeted Therapies in Transthyretin Cardiac #Amyloidosis from #HFSA2025 – to participate, visit: https://t.co/RLSpehUl2R https://t.co/p3Btn6Grvg

[Nattawat Klomjit @basmeomeo]

Not only AL! How many amyloidosis type are there that are recognized by the ISA?
~~➡️➡️ 42 types!
-Acquired
-Genetic
-Iatrogenic

[AMYLOIDOSIS ALLIANCE @AmyloidosisA]

🧬 Not all forms of Amyloidosis are hereditary — but they all change lives.
Some types are genetic 🧑‍🧑‍🧒‍🧒 Others appear without warning. 😢But every form deserves recognition, understanding, and proper care. 👩🏻‍⚕️

🎗️Every voice can make a difference 📣

[Amyloidosis Research Consortium @Amyloidosis_ARC]

Many #amyloidosis patients face not only a devastating disease but also delayed or missed diagnoses. With treatments available and more in development, faster diagnosis is critical to improving the lives of patients.

Learn more about ARC's impact: https://t.co/jMGnKzs2j4

[Claudio Tinoco Mesquita @ctinocomesquita]

🚨 New Publication! 🚨
Our team at @UFF_oficial, with @almallahmo , just published a systematic review and meta-analysis in the @JNCjournal : Comparison of PET-CT and CZT-SPECT on MBF measurement :
✅ Good agreement between CZT and PET ! Amazing job : @daviyahiro

[ASNC Society @MyASNC]

ICYMI: Cardiac PET & PET/CT have earned 🆕 indications in recently published guidelines from the ACC/AHA, @escardio, & the @ISHLT.

To help you translate these recommendations into practice, @JNCjournal published a State-of-the-Art Review article documenting where PET is now indicated for imaging in IHD, cardiac sarcoidosis, cardiac #amyloidosis, endocarditis, & vasculitis. Authored by Maria Alwan, MD, et al., this article is a must-read!
🔗https://t.co/I8w0Gug65e

[Journal of Nuclear Cardiology @JNCjournal]

Left ventricular myocardium-to-blood ratio >1.5 on 99mTc-HMDP SPECT/CT accurately detects ATTR-CM @helsinkiuni #cvnuc #amyloidosis

Read now👉https://t.co/MdnXFkvYQI

[Journal of Nuclear Cardiology @JNCjournal]

Is bone avid tracer cardiac scintigraphy always the preferred approach to screen at risk populations for TTR cardiac amyloidosis? @MasriAhmadMD @ColumbiaCardio @OHSUCardio #cvnuc

Read both sides of the debate👇
https://t.co/YgcWrXNuZC